FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

FOCUS ON RESEARCH Previous Volume 358:664-665 February 14, 2008 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hauser, S. L. PubMed Citation

A phase 2 clinical trial of rituximab in the treatment of multiple sclerosis reported by Hauser et al. in this issue of the Journal (pages 676–688) provides important insights into the biology of the disease. The study showed that rituximab reduces disease activity in patients with relapsing–remitting multiple sclerosis; patients treated with rituximab had a substantial reduction in the number of clinical relapses and the number of contrast-enhancing lesions detected on magnetic resonance imaging (MRI).

It is generally accepted that the MRI equivalent of an acute relapse is the disruption of the blood–brain barrier evidenced by increased signal after the . . . [Full Text of this Article]

Source Information

Dr. McFarland is a senior investigator in the Neuroimmunology Branch of the National Institute of Neurological Disorders and Stroke, Bethesda, MD.

This article has been cited by other articles:

• Dubois-Dalcq, M., Williams, A., Stadelmann, C., Stankoff, B., Zalc, B., Lubetzki, C. (2008). From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases. Brain 0: awn076v1-awn076 [Abstract] [Full Text]